Agenus Inc. heads into Monday's earnings with short sellers adding pressure and the stock near multi-month lows.
Short interest is the dominant setup story here. At 13.5% of free float, bears hold a meaningful position — and they have been adding to it. Short interest climbed roughly 12.5% over the past month, with the pace accelerating over the last week, up another 4.2%. The stock has fallen 24% over the past month to $3.58 and dropped a further 6.3% on the week, giving shorts a tailwind as they push into the print.
The borrow market reflects growing conviction on the short side, but remains far from extreme. Cost to borrow has jumped 57% in the past week to 1.14% APR — still modest in absolute terms, but the direction of travel is notable. Availability is not yet at distressed levels, suggesting the lending pool still has capacity for new shorts to enter. The ORTEX short score of 70.5 ranks in the bottom decile for the sector — a reading that flags elevated short-side pressure relative to peers.
Options tell a different story. Call positioning actually dominates the options market, with the put/call ratio at just 0.15 — close to the middle of its 20-day range and well below the 52-week high of 0.63. There is no meaningful hedging demand heading into the release. That divergence is the central tension of the setup: options traders are not bracing for a sharp move, while short sellers have been methodically building.
The analyst picture is limited and largely stale. Coverage is sparse — HC Wainwright and Baird are the primary voices on record, both carrying Neutral or Buy ratings as of mid-2025. The most recent logged action was a reiteration from HC Wainwright in September last year at a $23 target, a level more than six times the current price; that gap is too wide to treat as actionable context. Bulls point to a promising immuno-oncology pipeline centred on botensilimab and balstilimab, including compassionate-use revenue generation and early positive signals from ex-US regulators. Bears flag the cash requirements of a clinical-stage biotech, the risk of safety signals emerging from active trials, and a crowded competitive landscape.
Past earnings reactions have been volatile. The most recent prior print on May 11 saw the stock fall nearly 10% in a single session. An earlier March event produced a 25% five-day gain. Monday's release will test whether the accumulated short interest and the stock's month-long slide reflect deteriorating pipeline confidence — or whether any positive update on botensilimab's regulatory pathway can unwind those positions.
See the live data behind this article on ORTEX.
Open AGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
